<DOC>
	<DOCNO>NCT00391391</DOCNO>
	<brief_summary>Primary Objective : To evaluate influenza strain non-inferiority Investigational Fluzone vaccine standard Fluzone® vaccine healthy subject age 6 35 month 3 8 year . Secondary Objectives : - To describe immunogenicity Investigational Fluzone vaccine standard Fluzone® vaccine healthy subject age 6 35 month 3 8 year . - To describe safety Investigational Fluzone vaccine standard Fluzone® vaccine healthy subject age 6 35 month 3 8 year .</brief_summary>
	<brief_title>Study Inactivated , Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine Infants Children</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Orthomyxoviridae Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : Aged 6 month 8 year yet 9 year day inclusion . Subject healthy , determined medical history . Institution Review Board ( IRB ) approve informed assent form sign eligible subject ( required local regulation ) and/or IRBapproved inform consent form sign subject 's parent ( ) legal representative ( independent witness require local regulation ) . Parent legal guardian willing able attend ( bring subject ) schedule visit comply trial procedure . Exclusion Criteria : Participation another clinical trial 4 week precede trial vaccination . Planned participation another clinical trial present trial period . Personal family history GuillainBarré Syndrome . Congenital acquire immunodeficiency , immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month , longterm systemic corticosteroid therapy inject oral corticosteroid immunomodulator therapy within six week study vaccine . Individuals taper dose schedule oral steroid last &lt; 7 day may include trial long receive one course within last two week prior enrollment . Systemic hypersensitivity egg , chicken protein , vaccine component , vaccine containing substance . Chronic illness stage could interfere trial conduct completion Received blood bloodderived product previous 3 month . Any vaccination 4 week precede follow trial vaccination ( Subjects take standard childhood vaccination ( ) follow Visit 3 blood draw ) . Known current human immunodeficiency virus ( HIV ) , hepatitis B ( HBsAg ) hepatitis C infection seropositivity . Known thrombocytopenia bleed disorder contraindicate IM vaccination . Acute medical illness , without fever , within last 72 hour oral temperature ≥ 37.5 °C ( 99.5 °F ) rectal temperature ≥ 38°C ( 100.4 °F ) time enrollment . History seizure . Received antibiotic therapy within 72 hour precede trial vaccination . Received allergy shot 7day period precede trial vaccination and/or schedule receive allergy shot 7day period trial vaccination . Any condition , opinion investigator would pose health risk participant .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>8 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Orthomyxoviruses</keyword>
	<keyword>Inactivated Split-virion influenza vaccine</keyword>
	<keyword>Infants</keyword>
	<keyword>child .</keyword>
</DOC>